COMP <GO>
IONS vs MRK // RSI-14 & 200D SMA MOMENTUM
Ionis Pharmaceuticals Inc. (NASDAQ) VS. Merck & Company Inc. Common Stock (new) (NYSE) • 15-METRIC TALLY: IONS 3
— MRK 11
▲ RSI-14 & 200D SMA MOMENTUM LEADER: MRK
LAST: $43.52 (-1.96%) • MKT CAP: $7.38B
rsi-technicals
43.1
LAST: $149.52 (+2.18%) • MKT CAP: $361.02B
rsi-technicals
56.9
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (IONS VS. MRK)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | IONS | MRK | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 96.00% | 74.80% | +21.20 | IONS | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | -20.90% | 20.70% | -41.60 | MRK | /roic <GO> |
| EV/EBITDA & P/E Valuation | — | 15.3x | — | TIE | /valuation <GO> |
| Free Cash Flow Yield | -4.34% | 3.42% | -7.76 | MRK | /fcf-yield <GO> |
| Operating Margin | -40.40% | 34.30% | -74.70 | MRK | /operating-margins <GO> |
| Net Profit Margin | -40.40% | 28.10% | -68.50 | MRK | /net-margins <GO> |
| Revenue Growth (YoY) | 33.80% | 1.30% | +32.50 | IONS | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 2.26% | -2.26 | MRK | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 1.08 | 5.19 | -4.11 | MRK | /balance-sheet <GO> |
| Piotroski F-Score Quality | 5/9 | 7/9 | -2.00 | MRK | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | 7.20% | 6.60% | +0.60 | MRK | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum ACTIVE | 43.1 | 56.9 | -13.72 | MRK | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | 1.09 | 0.92 | +0.17 | IONS | /macro-sensitivity <GO> |
| Forward P/E Multiple | 22.0x | 18.4x | +3.60 | MRK | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $7.38B | $361.02B | -$353.64B | MRK | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | IONS REV | MRK REV | IONS GROSS % | MRK GROSS % | IONS FCF | MRK FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $943.7M | $65.01B | 98.3% | 74.8% | -$320.0M | $12.36B |
| FY 2024 | $705.1M | $64.17B | 98.4% | 76.3% | -$546.2M | $18.10B |
| FY 2023 | $787.6M | $60.12B | 44.0% | 44.0% | -$343.0M | $10.30B |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
IONS // BETA 1.09
MRK // BETA 0.92